11-1-2012

Effects of scleroderma antibodies and pooled human immunoglobulin on anal sphincter and colonic smooth muscle function.

Jagmohan Singh  
*Thomas Jefferson University*

Sidney Cohen  
*Thomas Jefferson University, Sidney.Cohen@jefferson.edu*

Vaibhav Mehendiratta  
*Thomas Jefferson University*

Fabian A. Mendoza  
*Thomas Jefferson University, Fabian.MendozaBallesteros@jefferson.edu*

Sergio A. Jimenez  
*Thomas Jefferson University, Sergio.Jimenez@jefferson.edu*

*See next page for additional authors*

**Let us know how access to this document benefits you**

Follow this and additional works at: [http://jdc.jefferson.edu/gastro_hepfp](http://jdc.jefferson.edu/gastro_hepfp)

🔗 Part of the [Gastroenterology Commons](http://jdc.jefferson.edu/gastro_hepfp)

**Recommended Citation**

[http://jdc.jefferson.edu/gastro_hepfp/14](http://jdc.jefferson.edu/gastro_hepfp/14)

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University’s Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Division of Gastroenterology and Hepatology Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.
As submitted to:

*Gastroenterology*

And later published as:

**Effects of Scleroderma Antibodies and Pooled Human Immunoglobulin on Anal Sphincter and Colonic Smooth Muscle Function**

*Volume 143, Issue 5, November 2012, Pages 1308-1318*

DOI: 10.1053/j.gastro.2012.07.109

**Short Title:** PooledhIgG REVERSES CHOLINERGIC DYSFUNCTION IN SSc

JAGMOHAN SINGH, SIDNEY COHEN, VAIBHAV MEHENDIRATTA, FABIAN MENDOZA, SERGIO A. JIMENEZ, ANTHONY J. DIMARINO, and SATISH RATTAN

*Department of Medicine, Division of Gastroenterology and Hepatology, and Jefferson Institute of Molecular Medicine and Scleroderma Center, Thomas Jefferson University, Philadelphia*

**Grant Support:** The work was supported by Grant Number RO1DK035385 from the National Institutes of Diabetes and Digestive and Kidney Diseases, and an institutional grant from Thomas Jefferson University.

**Abbreviations Used in this Paper:** BeCh, bethanechol (M3-R agonist); EFS, electrical field stimulation; ELISA, enzyme-linked immunosorbent assay; HISMF, human IAS SMC membrane fractions’ lysate; IAS, internal anal sphincter; IF, immunofluorescence; IFI, IF intensity; IgG, immunoglobulin; pooledhIgG, pooled human immunoglobulin; NIgG, IgGs from normal subjects; M3-R, muscarinic type3 receptor; M3-RL2, second extracellular loop peptide of M3-R; M3-RL3, third loop peptide of M3-R; SMC, smooth muscle cells; SSc, systemic sclerosis or scleroderma; SScIgG, IgGs from scleroderma patients
Corresponding Author: Dr. Satish Rattan, Professor of Medicine; 901 College, Department of Medicine, Division of Gastroenterology & Hepatology, 1025 Walnut Street, Philadelphia, PA 19107; Tel # (215) 955-5614; Fax # (215) 923-7697

Disclosures: The authors have nothing to disclose

Involvement of Authors with the Manuscript:
Jagmohan Singh in data acquisition, analysis and interpretation; and statistical analysis; Sidney Cohen in the enrolment and follow up of scleroderma patients; Vaibhav Mehendiratta in the human blood samples’ collection and ms preparation; Fabian Mendoza in the isolation and purification of SScIgGs; Sergio A. Jimenez in isolation and purification of scleroderma IgGs and data interpretation; Anthony DiMarino in the follow up of patients; and Satish Rattan in funds procurements, concept and design, interpretation of data, and study supervision

Abstract:
BACKGROUND & AIMS: Patients with systemic sclerosis (SSc) have impairments in gastrointestinal smooth muscle function. The disorder has been associated with circulating antibodies to cholinergic muscarinic type-3 receptor (M3-R). We investigated whether it is possible to neutralize these antibodies with pooled human immunoglobulin (Ig)Gs (pooledhIgG).

METHODS: We studied the effects of IgGs purified from patients with SSc (SScIgGs) on cholinergic nerve stimulation in rat colon tissues. We also examined the effects of SScIgGs on M3-R activation by bethanechol (BeCh), M3-R occupancy, and receptor binding using immunofluorescence, immunoblot, and ELISA analyses of human internal anal sphincter (IAS) smooth muscle cells (hSMCs), before and after administration of pooledhIgG. Functional displacement of M3-R occupancy by the SScIgGs was compared with that of other IgGs during the sustained phase of BeCh-induced contraction of intact smooth muscles from rats.

RESULTS: SScIgG significantly attenuated neutrally mediated contraction and acetylcholine release in rat colon as well as BeCh-induced sustained contraction of the IAS smooth muscle. In immunofluorescence analysis, SScIgG co-localized with M3-R. In immunoblot and ELISA analyses, M3-R loop-2 peptide and human IAS SMC membrane lysates bound significant amounts of SScIgG, compared with IgGs from healthy individuals and pooledhIgG. Binding was significantly attenuated by application of pooledhIgG, which by itself had no significant effect. Incubation of samples with pooledhIgG, or mixing pooledhIgG with SScIgG before administration to tissues, significantly reduced binding of SScIgG, indicating that pooledhIgG prevents SScIgG blockade of M3-R.

CONCLUSIONS: In studies of rat and human tissues, pooled human IgGs prevent and reverse the cholinergic dysfunctions associated with the progressive gastrointestinal manifestations of SSc, by neutralizing functional M3-R antibodies present in the circulation of patients with SSc.

Keywords: connective tissue disease; smooth muscle atrophy, fibrosis, animal model, antibody
**Introduction**

Scleroderma or systemic sclerosis (SSc) is a progressive autoimmune connective tissue disease associated with progressive fibrosis of skin and numerous internal organs.\(^1\) The gastrointestinal (GI) tract is the most common internal organ system affected in SSc with as many as 90% of the patients developing esophageal symptoms.\(^2,3\) Interestingly, a large percentage of SSc patients display involvement of the anorectum, causing alterations of the IAS function and frequent fecal incontinence.\(^4,6\)

GI dysmotility in SSc is believed to be neuropathic in origin, with subsequent smooth muscle atrophy and fibrosis.\(^2\) The early stages may involve neuropathic changes in the cholinergic innervation, and in the latter stages there are myopathic changes.\(^2,7\) Following earlier studies by Bacman and colleagues on the presence of circulating M\(_{3}\)-R in patients with Sjögren’s syndrome,\(^8\) Goldblatt et al.\(^9\) demonstrated the presence of such antibodies in SSc patients. These antibodies caused significant dysfunction in the mouse colonic smooth muscle contraction induced by the M\(_{3}\)-R agonist, carbachol. These studies suggested that neuropathic gastrointestinal dysfunction caused by circulating antibody interference with cholinergic innervation was responsible for GI dysmotility in SSc. Our recent studies using isolated SMCs of the rat IAS demonstrated that SScIgGs cause ~50% inhibition of M\(_{3}\)-R activation and suggested that this mechanism in part is responsible for the GI smooth muscle myopathy in SSc.\(^10\) None of the above studies, however, neither examined the status of the actual cholinergic innervation and its effects in human SMCs, nor investigated the possible reversal of SScIgGs’ effects.

Because of the lack of clear understanding of the SSc pathophysiological mechanism/s, there is no effective disease modifying treatment for SSc. Pooled human IgG (pooledhIgG)
also known as intravenous immunoglobulin (IVIG) has been clinically employed as a potent immunomodulating agent in various immune-mediated disorders.\textsuperscript{11-13} The use of pooledhIgG for the treatment of SSc has been supported by studies in the tight skin (TSK) animal model of SSc demonstrating that pooledhIgG may cause beneficial effects\textsuperscript{14} either by counteracting antifibroblast antibodies or decreasing expression of the type I collagen gene,\textsuperscript{15} as well as by modulating the secretion of profibrotic cytokines TGF\textbeta{}1 and IL-4.\textsuperscript{14,16} However, the exact mechanisms of action of pooledhIgG in SSc are not known. Thus, owing to the potential pathogenetic role of circulating antibodies in SSc-related GI dysmotility it will be important to determine the effect of pooledhIgG in SSc in inhibition of the effect of SScIgGs against M\textsubscript{3}-R.

In the present study we determined the site of action of the M\textsubscript{3}-R autoantibodies present in SScIgGs using rat colon to assess a cholinergic involvement, and then assessed the myopathic changes using human IAS SMC and rat IAS smooth muscles. The studies also investigated the role of pooledhIgG in reversing the cholinergic blockade by SScIgGs in these systems.

**Materials and Methods**

*Isolation and Purification of IgGs from SSc Patients and Normal Volunteers*

Six female patients with SSc fulfilling the criteria for SSc classification of the American College of Rheumatology\textsuperscript{17} were studied. The studies were approved by the Institutional Review Board of Thomas Jefferson University. Disease duration varied from 4 to 42 years. All patients had typical esophageal manometric features and two had fecal incontinence.\textsuperscript{18} Total IgGs were purified from plasma of the six SSc patients (SScIgGs) and two normal volunteers (NIgGs), by use of recombinant protein G-Sepharose 4B conjugate (Zymed Laboratories, San Francisco, CA) and disposable spin-out columns (G Biosciences, Maryland Heights, MO) as published previously.\textsuperscript{19}
Human IAS Tissue Samples and SMCs Isolation

Human IAS smooth muscle tissue samples were obtained from five subjects who underwent surgical removal of the anorectal region. SMCs from the circular smooth muscle layer of the IAS were isolated as described previously. Isolated cells were resuspended in DMEM growth medium with 5% fetal bovine serum and antibiotics on Lab-Tek II chamber slides (Nulgene Nunc International, Naperville, IL) at 37°C and 5% CO₂ in an incubator with regulated humidity.

Experiments in Human SMCs

Effect of SScIgGs, NIgGs and PooledhIgG on Human IAS SMC Contraction

The SMCs isolated as described above were divided into different aliquots, and their responses to bethanechol (BeCh; 10⁻⁹ to 10⁻⁴ M) before and after SScIgG, NIgG, pooledhIgG (0.1 to 1 mg/ml) and the combination of either pooledhIgG and SScIgG or pooledhIgG and NIgG (0.1 to 1 mg/ml each) for 10 min, were determined. In some experiments, we also examined the effects of higher concentrations (10 mg/ml) of pooledhIgG. The cells were then fixed with acrolein (final concentration 1%) and cell length was measured by using digital micrometry. To determine the selectivity of action of the SScIgG on the M₃-R activation by BeCh, we compared the effects of different IgGs and their combinations on α₁-adrenoceptor (α₁-AR) activation by phenylephrine (10⁻⁹ to 10⁻⁴ M), and K⁺-depolarization with KCl (2.5 mM to 40 mM).

Immunofluorescence Analysis

The human IAS SMCs were quickly rinsed with Dulbecco’s phosphate-buffered saline (DPBS) and non specific antibody binding sites were blocked with 1% FBS in DPBS. To determine the membrane binding efficiency of SScIgG, vs NIgG and pooledhIgG, SMCs were incubated with 5 µg/ml of these antibodies for different time points (0 to 30 min) at 37°C, and fixed with acetone for 10 min at −20°C. The cells were then washed three times with DPBS
and stained with the anti-human IgG-FITC-conjugated antibody as described previously. Cells were co-stained with 5µg/ml of anti-M₃-R antibody, as an internal control to detect colocalization of M₃-R with SScIgG in human IAS SMCs. These cells were rinsed with DPBS and stained with anti rabbit-TR-conjugated antibody. The cells were finally stained with nuclear staining dye DAPI and images were taken employing a Nikon Eclipse 80i microscope as described previously.

**Immunoﬂuorescence Intensity (IFI) Calculation**

IFI was calculated by using NIS Elements 3.1 software by two different methods as follow:

a). Intensity per unit area: For this purpose, 20 µm² of cell membrane area was selected at four different sites of the cell membrane and pixel intensity under this area was calculated and plotted as a bar graph (Fig. 2B and E). The above procedure was repeated in 20 randomly selected cells and calculated as means ± SE.

b). Line graph method: For this purpose, intensity under a line of 1-µm width across the cell avoiding the nucleus was calculated and plotted for the membrane IFI of different IgGs (Fig. 3A). The Pearson’s colocalization coefficient was determined for each cell and Mean ± SE was calculated and plotted (Fig. 3B).

**Western Blot (WB) Analyses for Interaction of SScIgGs vs. NIgGs and pooledhIgG with M₃-R**

These studies were performed to determine the binding of SScIgG vs. NIgG, and pooledhIgG to M₃-R in human IAS SMC membrane fractions (HISMF) prepared following a previously described method. The membrane protein was electrophoresed on 7.5% SDS-PAGE and transferred to a PVDF membrane by using iBlot. The membrane was subdivided into five equal parts that were kept in blocking buffer (5% bovine serum albumin in Tris buffer saline pH 7.2) for 1 h. These membranes were separately incubated overnight at 4°C with 5 µg/ml of M₃-R antibody, SScIgG, NIgG, pooledhIgG, and pooledhIgG+SScIgG, washed three
times with TBS containing 0.1% Tween (TBST), and stained with corresponding HRP-conjugated secondary antibodies. The membranes were washed three times for 10 min with TBST, and stained with tertiary antibody against HRP (Chemi IR detection system from LI-COR biosciences) for 1 h at RT in TBST containing 0.002% SDS. The membranes were washed and scanned with a LI-COR Odyssey Imaging System infrared scanner, and relative densities of M₃-R and human IgGs were plotted using Image-J (NIH).¹⁰ Na⁺-K⁺ ATPase (a membrane marker) antibody was used as a loading control.

**Enzyme-Linked Immunosorbent Assay (ELISA)**

To determine direct binding of SScIgG to the M₃-R and its interaction with pooledhIgG in the human IAS SMCs, we performed ELISA studies employing an ELISA kit (NB-E10632 from Novatein Biosciences, Inc., Cambridge, MA) using different concentrations of purified M₃-R peptide or HISMF according to the manufacturer’s instructions. These experiments provided the optimal concentrations of M₃-R peptide and the HISMF to determine the M₃-R binding.

To determine the M₃-R binding, 400 µg/ml of HISMF and peptides corresponding to the M₃-R second extracellular loop-2 (M₃-RL2; KRTVPPGECFIQFLSEPTITFGTAI, amino acids 213–237) and Loop-3 (M₃-RL 3; NTFCDSCIPKTWFN, amino acids 514–527) at a concentration of 400 pg/ml were separately dissolved in the carbonate buffer and adsorbed onto separate multiwell plates used for ELISA.²¹ From 0 to 6 µg/ml of M₃-R antibody, SScIgG, NIG, pooledhIgG, and pooledhIgG+SScIgG were added to these multiwell plates and incubated at 37°C for 1 h. Plates were washed three times with DPBST and incubated for 1 h at RT with anti-rabbit-HRP-conjugated for M₃-R antibody and anti-human-HRP-conjugated secondary antibodies for SScIgG, NIG, pooledhIgG and pooledhIgG+SScIgG and washed
three times with DPBST and 100 µl of TMB substrate was added and kept for 15 min at RT. Following substrate addition, 100 µl of Stop solution was added to each well and absorbance was recorded at 450nm with ELISA reader.

**Neutralization Studies**

For this purpose 400 pg/ml M₃-R peptide was adsorbed on multiwell plates (used for ELISA) and the effect of pooledhIgG on the maximal binding of the SScIgG (5 µg/ml) to the M₃-R peptide was determined by ELISA. We substituted SScIgG alone with the mixture of SScIgG+pooledhIgG (mixed at 37°C for 1h; pooledhIgG concentrations ranged from 0 to 15 µg/ml diluted in PBS). As a negative control for the pooledhIgG effects, we used inactivated pooledhIgG (by proteinase digestion followed by boiling). The OD readings obtained using the combination of pooledhIgG+SScIgG were compared with those of the maximal OD reading obtained with M₃-R peptide and SScIgG alone. To determine the neutralization of the M₃-R binding with the SScIgGs by pooledhIgG in the IAS SMC membrane, we followed the procedure described above except for substitution of M₃-RL2 with 400 µg/ml of HISMF.

**Experiments using Intact Rat Colon and IAS Smooth Muscles: Smooth Muscle Strips Preparation and Isometric Tension Recording**

**Cholinergic Nerve Stimulation Experiments**

Male Sprague-Dawley rats (300–350 g) were euthanized by decapitation, and the lower portion of the colon was surgically removed and transferred to oxygenated (95% O₂ + 5% CO₂) Krebs physiological solution (KPS) at 37°C. The composition of KPS (in mM) was: 118.07 NaCl, 4.69 KCl, 2.52 CaCl₂, 1.16 MgSO₄, 1.01 NaH₂PO₄, 25 NaHCO₃, and 11.10 glucose. The colonic smooth muscle strips (~0.5x7 mm) from the circular smooth muscle layer were prepared for the recording of isometric tension using 2 ml organ baths as described previously.²⁴,²⁵ These smooth muscle strips were then transferred to 2 ml organ baths...
containing oxygenated KPS and allowed to equilibrate for 1-2 h. To determine the effects of cholinergic nerve stimulation, electrical field stimulation (EFS; 10 V, 0.25 to 10 Hz, 4 sec train, each pulse of 0.5 ms) was delivered using a Grass stimulator (model S88; Grass Instruments Co., Quincy, MA). The EFS responses (percent maximal increase in the basal activity) were quantified before and after tetrodotoxin (TTX; $10^{-6}$ M), atropine ($10^{-7}$ M), darifenacin ($10^{-7}$ M), NIgG and SScIgG (1mg/ml), pooledhIgG (10 mg/ml), and pooledhIgG (10mg/ml)+SScIgG (1mg/ml).

**Acetylcholine (ACh) Measurements**

Rat colonic smooth muscles were prepared for the EFS as described above. The muscle bath perfusates were collected in the basal state, and following EFS before and after $0\text{Ca}^{2+}$, TTX ($10^{-6}$ M), and SScIgG (1mg/ml) before and after pooledhIgG. ACh measurements were made using choline/acetylcholine Quantification kit (BioVision, Milpitas, CA) following manufacturer’s instructions. Data were quantified employing fluorometric (Fluorometer Optima Micropipette Reader; BMG Labtech Ortenberg, Germany) analysis with MARS software.

**Functional Displacement of M$_3$-R Experiments using Intact IAS Smooth Muscle**

We examined the responses to SScIgG, NIgG and pooledhIgG (0.1 to 1 mg/ml) on the sustained phase of IAS contraction by BeCh ($10^{-4}$ M). These effects were compared with those of M$_3$-R antagonist darifenacin ($10^{-9}$ M to $5\times10^{-8}$ M). The basal tone in each smooth muscle strip of the colon and IAS was determined at the end of each experiment by the administration of EDTA (50 mM) and $0\text{Ca}^{2+}$. All experimental protocols were approved by the IACUC of Thomas Jefferson University in accordance with the recommendations of the American Association for the Accreditation of Laboratory Animal Care.
Drugs and Chemicals

BeCh, KCl, phenylephrine, TTX, atropine, and M₃-R antibody were purchased from Sigma Aldrich (St. Louis, MO). PooledhIgG (IVIG) was a generous gift from PriviGen (King of Prussia, PA). M₃-R loop-2 (M₃-RL2) and loop-3 (M₃-RL3) peptides were from Peptide 2.0 Inc. (Chantilly, VA), Darifenacin (M₃-R selective antagonist) was a gift from Pfizer (Sandwich, Kent, UK). Na⁺-K⁺ ATPase monoclonal antibody (a membrane marker) was from Santa Cruz Biotech. (Santa Cruz, CA).

Statistical Analysis

Data are presented as means ± SE of multiple experiments. P values less than 0.05 were considered statistically significant. The concentration-response curves were fitted by nonlinear regression using the computer software Prism (GraphPad Software, San Diego, CA).

Results

Effect of SScIgGs on Cholinergic Nerve Stimulation in the Colon: Studies in Intact Rat Colonic Smooth Muscles

EFS caused a frequency-dependent increase in the contraction of the colonic smooth muscles, that was attenuated by TTX, atropine, and darifenacin (*; p<0.05; n=6; Fig. 1A), suggesting that EFS causes contraction of the colonic smooth muscle via cholinergic nerve stimulation, partly through M₃-R activation. The data further showed that SScIgGs (in contrast with pooledhIgG) caused significant suppression of the EFS-induced cholinergic contraction (*; p<0.05; n=6). The latter effect was reversed by 10mg/ml pooledhIgG to the level that was not significantly different from the control values (p>0.05; n=6).
**Effect of SScIgGs on EFS-Evoked ACh Release in Intact Rat Colonic Smooth Muscles**

Direct measurements of ACh from myenteric neurons revealed that EFS causes a significant increase in ACh release, which was significantly attenuated by 0Ca$^{2+}$, TTX as well as by SScIgG (**; p<0.05; Fig. 1B; n=4). A complete obliteration of the EFS-evoked release of ACh by 0Ca$^{2+}$ and TTX suggests definitive neurotransmitter release of ACh. The suppressant effects of SScIgGs on ACh release were reversed by pooledhIgG (*; p<0.05; n=4), whereas pooledhIgG by itself had no significant effects on basal release of ACh (p>0.05).

**Effect of SScIgG vs. NIgG and PooledhIgG on BeCh-Induced Contraction of Human IAS SMCs**

SScIgGs significantly attenuated the contraction of BeCh-induced M$_3$-R activation in human IAS SMCs (*; p<0.05; n=6), and that inhibition was significantly reversed by pretreatment of the SMC with 1mg/ml pooledhIgG (**; p<0.05). The maximal effective concentration of BeCh ($10^{-4}$ M), in control experiments induced a SMC contraction of 19.7 ± 1.5%. SScIgG (1mg/ml) significantly attenuated this response to 5.7 ± 0.1% (~70% inhibition; *; p<0.05; n=6), and pooledhIgG (10 mg/ml) reversed this to 18.6 ± 2.4%, a value not significantly different from controls (p<0.05; n=6; Fig. 1C). In contrast, the contractile effects of phenylephrine (alpha1-adrenoceptor or $\alpha_1$-AR activator) and K$^+$ depolarization by KCl were not modified by SScIgG (data not shown). These data demonstrate the selectivity of the suppressant effects of SScIgG in the M$_3$-R activation in the human IAS SMC.

**M$_3$-R Occupancy by SScIgGs vs. NIgGs and PooledhIgG in Human IAS SMC**

Data showed that SScIgG binds to the SMCs with M$_3$-R selective immunofluorescence intensity (IFI) saturating at 20 min (IFI of M$_3$-R using M$_3$-R antibody was considered as 100 %; Fig. 2A,B). Significant IFI with SScIg was observed at 5 and 10 min as 79.57 ± 5.43 and 89.47 ± 6.24%, respectively (*; p<0.05; n=6). Therefore, a 10 min time frame was selected for
the subsequent experiments with SScIgG. In contrast with the SScIgG, NIgG and pooledhIgG (14 ± 1.5 and 16 ± 2.2%, respectively) had significantly less binding (*; p<0.05; Fig. 2C,D,E). Collectively, these data reveal that SScIgG has significantly higher binding to the IAS SMC membrane than NIgG and pooledhIgG. Immunofluorescence (IF) analysis also showed a significant (*; p<0.05; n=6) colocalization of the M₃-R and SScIgG binding to the human SMC membranes, as determined by the secondary antibodies conjugated with TR and FITC, respectively (*; p<0.05; n=6; Fig. 3A,B). This colocalization was not observed with either NIgG or pooledhIgG.

**Functional Displacement of M₃-Receptor (M₃-R) Occupancy by SScIgG in Rat IAS Smooth Muscle**

These studies were carried out in the tonic component of the rat IAS smooth muscle contraction induced by 10⁻⁴ M BeCh. As shown in Fig. 4A, 10⁻⁴ M BeCh caused an initial phasic contraction followed by the sustained or tonic component. The sustained component allowed sufficient time to examine different concentrations of NIgG, SScIgG or pooledhIgG and darifenacin. As shown in Fig. 4A, only SScIgG significantly attenuated the tonic component, because of the interference of M₃-R occupancy by the SScIgGs as it resembled the effect of darifenacin. Typical tracings of the effect of the functional occupancy and reversal of the BeCh-induced M₃-R activation by SScIgG and darifenacin are shown in Fig. 4B.

**Assessment of SScIgG, NIgG and PooledhIgG Binding to M₃-R using Western Blot Analysis in Human IAS SMCs**

Western blot analysis was used to confirm the binding of SScIgG to M₃-R in HISMF, and its reversal by pooledhIgG. When electrophoresed in parallel with the M₃-R antibody, SScIgG (and not NIgG and pooledhIgG) revealed a specific protein band coinciding with the M₃-R in HISMF (Fig. 5). The western blot analysis further showed that pretreatment of the SMC
membranes with pooledhIgG added either 30 min before SScIgG, simultaneously or with the premixed solution of SSCIgG with pooledhIgG (incubated at 37°C for 30 min) significantly decreased binding of SScIgG with M₃-R. A relative intensity graph was plotted by considering the M₃-R band intensity as 1.0. The Relative intensity of the SScIgG band was significantly higher (0.57 ± 0.04; *; p<0.05) than with NIgG and pooledhIgG (0.03 ± 0.03 and 0.02 ± 0.04, respectively). SScIgG (5 µg/ml) combined with pooledhIgG displayed a significantly decreased binding to the M₃-R (from 0.57 ± 0.04 to 0.22 ± 0.04; *; p<0.05, n=6). Thus collectively, these data show the presence of significant binding of SScIgG to the M₃-R in the human SMC membranes that is inhibited by pooledhIgG pretreatment.

Assessment of SScIgG, NIgG and PooledhIgG Binding to M₃-R and Influence of PooledhIgG employing Human IAS SMC Membrane Lysate and M3-R loop-2 Peptide

M₃-R specific ELISA studies revealed a concentration-dependent increase in the binding with the standard M₃-R peptide and the HISMF (Fig. 6A), with the maximal binding at 300 pg/ml and 300 µg/ml, respectively. Following this, we used multiwell plates (used for ELISA) preadsorbed with the maximal concentration (300 µg/ml) of the HISMF and performed ELISA using different concentrations of the IgGs for M₃-R binding analysis (Fig. 6B). The data showed that SScIgG (and not NIgG and pooledhIgG) binds to HISMF significantly in a concentration-dependent manner and the maximal OD at 5µg/ml of the lysate was 0.71 ± 0.05 (*; p<0.05; n=6). Pretreatment of the SScIgG with pooledhIgG (SScIgG+pooledhIgG) caused a significant decrease in the binding of the SScIgG to the M₃-R as reflected by a decrease in the OD (from 0.71 ± 0.05 to 0.43 ± 0.024; *; p<0.05; n=6; Fig. 6B). These data suggest that the membranes have M₃-R domains that selectively bind with the SScIgGs.
To further confirm these observations, we used multiwell plates (used for ELISA) preadsorbed with the maximum concentration of M3-R second loop peptide (M3-RL2; 5µg/ml), followed by the different concentrations of the IgGs. The data show a concentration-dependent increase in M3-R binding with SScIgG (*; p<0.05; Fig. 6C) and not with NIgG or pooledhIgG (p>0.05). However, pretreatment with pooledhIgG (SScIgG+pooledhIgG), caused a significant decrease in the binding of the SScIgG to the M3-R (*; p<0.05). In contrast when M3-RL2 peptide was replaced with the M3-R third loop peptide (M3-RL3), there was no significant binding (data not shown). These data validate the results obtained with the intact cell membrane studies, and suggest that SScIgGs display significant and specific binding to the M3-R in the IAS SMC and further confirm a significant attenuation of this binding by pooledhIgG.

**PooledhIgG Neutralizes the SScIGs in vitro: Studies using Human IAS SMC Membrane Extracts**

In these experiments, we determined the maximal OD following incubation of 5 µg/ml of SScIgGs from different patients in multiwell plates (used for ELISA) preadsorbed with 400 pg/ml of M3-RL2 (Fig. 7). Pretreatment with pooledhIgG caused a significant and concentration-dependent decrease in this maximal OD; 15 µg/ml of pooledhIgG decreased the OD from 0.77 ± 0.34 to 0.41 ± 0.05 (*; p<0.05; n=6; Fig. 7A). However, inactivated pooledhIgG failed to cause any decrease in the interaction between SScIgG and M3-RL2. Interestingly, similar data were obtained when HISMF (400 mg/ml; Fig. 7B) instead of M3-RL2 was used. Thus, these data show that neutralization of the SScIgG with pooledhIgG causes a decrease in the M3-R binding by the SScIgGs.

**Discussion**
These studies indicate several important points. Firstly, sera from patients with SSc contain antibodies of the IgG class that act both at the myenteric nerves and at the smooth muscle cell membrane receptors. Secondly, these antibodies reversibly block cholinergic nerve and muscle functions. Thirdly, the effects of these antibodies can be inhibited by pooledhIgG. Finally, the studies show that one of the prominent sites of action of these antibodies is at M$_3$-R and that this interaction can be effectively reversed by pooledhIgG. The proposed model of the pathophysiological actions of SScIgGs and their reversal by pooledhIgG (via neutralization of SScIgGs) in the gastrointestinal tract are given in Fig. 7.

The exact pathogenesis of GI dysmotility in SSc remains elusive. SSc patients are known to harbor various anti-nuclear antibodies including anti-DNA-topoisomerase I (anti-topo I), anti-centromere (CENPs-A, -B, -C and -D), and anti-RNA-polymerase III antibodies. Although, the specific nature of antibodies present in the sera of GI symptomatic SSc patients antibodies that may recognize epitopes present in the GI tract is not known, earlier studies from mouse colon smooth muscle and rat IAS SMCs suggested these antibodies interfere with M$_3$-R activation.

The present studies provide evidence in favor of cholinergic blockade by M$_3$-R inactivation at the neural as well as at the muscular levels and show that SScIgGs cause significant impairment of cholinergic contraction of the colon. Importantly, these SScIgG-impaired responses are significantly and selectively reversed by pooledhIgG. An effect of SScIgGs on the cholinergic myenteric neurons was demonstrated by the significant decrease in the actual release of ACh in these preparations, which is reversible by pooledhIgG.

Evidence for the partial effects of the SScIgGs at the myogenic level comes firstly from studies showing that the SScIgGs (and not NIgGs and pooledhIgG) attenuate the IAS SMC
contractility caused by BeCh-induced M₃-R activation, while SScIgGs do not modify SMC contraction by other agonists. Secondly, IF studies in the SMCs show that SScIgGs colocalize with M₃-R. Thirdly, the binding of M₃-R by the SScIgGs is further evident by the WB studies where SMC membranes incubated with the SScIgGs reveal a M₃-R-specific band. Fourthly, the binding of SScIgGs and interference with M₃-R by SScIgGs is further evident from the functional displacement of M₃-R occupancy. Herein, SScIgGs (and not NIgGs) inhibit BeCh-induced sustained contraction of intact IAS smooth muscle of rat in a concentration-dependent manner. Finally, HISMF causes concentration-dependent increase in the M₃-R binding when multiwell plates (used for ELISA) are preadsorbed with M₃-R-specific antibody. In addition, SScIgGs cause selective and concentration-dependent increase in the binding when multiwell plates pre-adsorbed with either HISMF or M₃-RL2 are used. The studies reveal that M₃-RL2 is critical for the binding of the SScIgGs to the M₃-R as the substitution of M₃-RL2 with M₃-RL3 produces no significant binding. Studies by Scarselli et al.²⁷ corroborate these findings for the critical role of M₃-RL2 in the M₃-R activation.

Thus, the results described here provide novel information demonstrating that the M₃-R inactivation caused by SScIgGs is reversible by pooledhIgG, via interference with the M₃-R occupancy. Pretreatment of SScIgGs with pooledhIgG significantly decreases the binding of SScIgGs to purified M₃-R peptide. This suggests the presence of anti-idiotypic antibodies in pooledhIgG that block the pathophysiological activity of anti-M₃-R antibodies in SScIgGs. Functional displacement of M₃-R occupancy by pooledhIgG is indicated by its ability to reverse the SScIgGs-induced inhibition of BeCh-induced sustained contraction of intact IAS smooth muscle. ELISA studies confirm that pooledhIgG reverses the SScIgGs-induced
decrease in the binding with purified M₃-R. Such data are similar whether multiwell plates are preadsorbed with the HISMF or the M₃-RL2 peptide.

Several possible mechanisms may explain the reversal of SScIgGs-induced M₃-R inactivation by pooledhIgG including neutralization, desensitization, internalization or degradation of the IgGs.

Present studies provide further evidence that pooledhIgG reverses M₃-R inactivation whether the cells are incubated with pooledhIgG followed by SScIgG or with the premixed SScIgGs and pooledhIgG. This is shown by IF, WB, ELISA, neutralization, and functional displacement of M₃-R occupancy studies. Therefore we suggest that the effects of pooledhIgG occur primarily by binding with the SScIgG thus neutralizing the effects of these antibodies in the circulation. This hypothesis is further supported by the observations that pooledhIgG forms an immune complex with IgGs interacting with Fcγ receptors on dendritic cells thus reducing the severity of autoimmune diseases. From the present data, we postulate that neutralization of these pathogenic antibodies by pooledhIgG may represent a novel approach for the treatment of SSc GI motility disorders by blocking cholinergic dysfunction induced by SScIgG. However, the exact mechanism, and the role of other pathways including possible removal of the SSc pathogenic antibodies in the therapeutic efficiency and efficacy of pooledhIgG remain to be determined. Previously reported studies on the effect of pooledhIgG in SSc patients have primarily focused on cutaneous and articular manifestations. Therefore, the present studies that identify a novel therapeutic and potentially mechanistic role of pooledhIgG in the GI dysfunction of SSc may represent a major step forward for the treatment of SSc.
In summary, the present studies provide evidence for the proposed mechanism for the M₃-R-mediated cholinergic dysfunction in SSc-related GI manifestations and its restoration by pooledhIgG. Collectively, we posit that neutralization of these pathogenic antibodies by pooledhIgG may in part relieve SSc-associated GI motility disorders by blocking cholinergic inhibition. Based on the long-term use of pooledhIgG in other autoimmune diseases, we suggest that pooledhIgG may provide a novel and safe therapy for the SSc-related GI motility disorders.

**References**


**Figure Legends**

**Fig. 1.** A. TTX, atropine, and darifenacin significantly attenuate the EFS-induced contraction of the rat colonic smooth muscle caused by EFS (*; p<0.05; n=6). SScIgG also causes significant
(*) p<0.05; n=6) attenuation of these EFS responses that is reversed by pooledhIgG to values not significantly different from those obtained in the control and the pooledhIgG alone experiments (p>0.05). B. EFS causes a significant (*) p<0.05; n=4) increase in ACh release that is significantly (**) p<0.05; n=4) mitigated not only by 0Ca2+ and TTX but also by SScIgG. The effects of SScIgG are reversed by pooledhIgG pre-treatment. C. SScIgG significantly (*) p<0.05; n=6) inhibits M3-R activation-induced human SMC contraction by BeCh. These inhibitor effects of SScIgG are restored by pooledhIgG in a concentration-dependent manner (significantly by 1mg/ml pooledhIgG; *), and almost completely by 10 mg/ml pooledhIgG to the levels that are not significantly different from control, NIG and pooledhIgG experiments (p>0.05).

Fig. 2. A. Time-dependent increase in the M3-R-specific IF intensity (IFI) in human IAS SMCs following treatment with (1:200 or 5 µg/ml) of M3-R antibody. B. Maximal IFI of human IAS SMC occurs following 20 min of incubation with the M3-R antibody. C. M3-R occupancy with SScIgG in the SMC membrane is significantly higher (*) p<0.05) as compared with NIG and pooledhIgG, as determined by IFI/unit area. D. An example of data collection for the intensity/unit area on the membrane. E. Quantitative data showing % maximal IFI/unit area with NIG, SScIgG, pooledhIgG (on the basis of 100% for M3-R antibody).

Fig. 3. A. Immunocytochemical colocalization of different IgG preparations (SScIgG, a; NIG, b; and pooledhIgG, c; (all FITC-conjugated; green)) and M3-R (TR-conjugated; red) and nucleus is stained blue with DAPI. Line graph analyses for the localization of these IgGs on the SMC membrane and their corresponding colocalization with M3-R are shown on the extreme right of each IgG plate. B) Bar graph data show significant colocalization of SScIgG (vs. NIG and pooledhIgG) with the M3-R at the SMC membrane.
Fig. 4. A. In control experiments M₃-R activation by BeCh causes a two phase contraction of the IAS; phasic followed by the tonic. SScIgG (but not NIgG and pooledhIgG) in resemblance with darifenacin (M₃-R selective inhibitor) causes significant and concentration-dependent decrease in the BeCh-induced sustained contraction (*; p<0.05; n=6). B. Actual tracings of the effect of darifenacin, SScIgG, NIgG, and pooledhIgG on the BeCh-induced sustained contraction of the IAS.

Fig. 5. Western blot analysis shows significant (*; p<0.05, n=6) binding of SScIgG with M₃-R (p<0.05) in contrast with the other IgGs, in human IAS SMC membrane fractions (HISMF). In addition, combination of pooledhIgG+SScIgG causes significant decrease in this binding (*; p<0.05; n=6).

Fig. 6. A. ELISA binding studies for M₃-R peptide and human IAS SMC membrane fraction (HISMF). A. OD concentration-curves using M₃-R standards and HISMF. B. Data show that M₃-R antibody and SScIgG bind with HISMF in a concentration-dependent manner (*; p<0.05; n=6), and pooledhIgG significantly decreases this binding. C. Similar data were obtained when M₃-R peptide (M₃-RL2) instead of HISMF is used.

Fig. 7. A. Neutralization studies via ELISA show that pooledhIgG (active and not inactivated pooledhIgG) causes significant and concentration-dependent decrease (*; p<0.05) in the binding of SScIgG at the M₃-RL2. B. Similar data were obtained when M₃-RL2 was replaced with the membrane lysates. In these experiments, maximal OD is first observed following the incubation of 400 µg of HISMF with 5 µg/ml of SScIgGs. C. A working model suggests that SScIgGs lead to gastrointestinal motility dysfunction by blocking M₃-R at the cholinergic neurotransmission at the neural and the SMC levels. Data further suggest that pooledhIgG neutralizes the SSc autoantibodies in the circulation thus attenuating these effects of SScIgGs.
on M₃-R inhibition. This neutralization may in part reverse the pathophysiology of SSC gastrointestinal smooth muscle dysfunction.
SScIgGs Attenuate Cholinergic Nerve Stim. (Studies in Rat Colon)

SScIgGs Decrease EFS-Evoked ACh Release (Studies in Rat Colon)

SScIgGs Attenuate Cont. of IAS SMCs (Studies in Human IAS SMCs)

**Fig. 1**

A

SScIgGs Attenuate Cont. of IAS SMCs (Studies in Human IAS SMCs)

- Control
- Normal IgG (1 mg/ml)
- SScIgG (1 mg/ml)
- Pooled hIgG (10 mg/ml)
- Pooled hIgG + SScIgG

% Decrease in SMC Length

Control  
SScIgG (1 mg/ml)  
Pooled hIgG (10 mg/ml)

Log [bethanechol] (M)

% Max. Contraction

Control  
Atropine (10^{-7} M)  
SScIgG (1 mg/ml)  
Pooled hIgG + SSclG

Log EFS Frequency (Hz)

B

SScIgGs Decrease EFS-Evoked ACh Release (Studies in Rat Colon)

- Control
- TTX (10^{-6} M)
- Atropine (10^{-7} M)
- Darifenacin (10^{-7} M)
- SSclG (1 mg/ml)
- Pooled hIgG (10 mg/ml)
- Pooled hIgG + SSclG

Acetylcholine (pmols/mg)

0 25 50 75 100

0.25 0.5 1 2 5 10

Log EFS Frequency (Hz)

C

SScIgGs Attenuate Cont. of IAS SMCs (Studies in Human IAS SMCs)

- Control
- Normal IgG (1 mg/ml)
- SSclG (1 mg/ml)
- Pooled hIgG (1 mg/ml) + SSclG
- Pooled hIgG (10 mg/ml) + SSclG

% Decrease in SMC Length

Control  
TTX (10^{-6} M)  
Atropine (10^{-7} M)  
SSclG (1 mg/ml)  
Pooled hIgG (10 mg/ml)  
Pooled hIgG + SSclG

Electrical Field Stimulation (10 V, 0.5 ms pulse, 5 Hz, 30 Sec train)
**Fig. 2**

**A**

0 1 2 5 10 20 30 Min.

**B**

Fluoresc. Intensity

SScIgG (1:200 or 5 μg/ml)

Time (min)

**C**

<table>
<thead>
<tr>
<th>IgGs</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td></td>
</tr>
<tr>
<td>SSc</td>
<td></td>
</tr>
<tr>
<td>PooledhlgG</td>
<td></td>
</tr>
<tr>
<td>M3-R Ab</td>
<td></td>
</tr>
</tbody>
</table>

**D**

**E**

Fluoresc. Intensity/ unit area

M3-R  N  SSc  PhlgG

Area = 20.00 μm²
Fig. 4

A

% Max. increase in IAS Tone

Time (min)

Bath $10^{-4}$ M

B

- $0.1$ - $0.3$ - $0.5$ - $1.0$ (mM) Pooled IgG
- $0.1$ - $0.2$ - $0.5$ - $1.0$ (mM) SSaIgG
- $0.0$ - $0.5$ - $1.0$ (mM) Dantrolene

- $0.1$ - $0.2$ - $0.5$ - $1.0$ (mg/mL) Pooled IgG
- $0.1$ - $0.2$ - $0.5$ - $1.0$ (mg/mL) SSaIgG
- $0.5$ - $1.0$ (mg/mL) Dantrolene

GM 2.0

GM 2.0

GM 2.0

GM 2.0

GM 2.0

GM 2.0
Fig. 5

[Image showing a bar graph with bars for M3, SSc, N, Pooled IgG, and Pooled IgG + SSc. The graph compares the relative intensity of M3-R and Na⁺-K⁺ ATPase across different IgG samples.]

<table>
<thead>
<tr>
<th>IgGs (5 μg/ml)</th>
<th>M3-R</th>
<th>SSc</th>
<th>N</th>
<th>Pooled IgG</th>
<th>Pooled IgG + SSc</th>
</tr>
</thead>
<tbody>
<tr>
<td>Relative Intensity</td>
<td><img src="#" alt="Graph Data" /></td>
<td><img src="#" alt="Graph Data" /></td>
<td><img src="#" alt="Graph Data" /></td>
<td><img src="#" alt="Graph Data" /></td>
<td><img src="#" alt="Graph Data" /></td>
</tr>
</tbody>
</table>

- M3-R: Comparison between M3 and SSc, N, Pooled IgG, and Pooled IgG + SSc.
- Na⁺-K⁺ ATPase: Comparison between M3 and SSc, N, Pooled IgG, and Pooled IgG + SSc.

* indicates statistical significance (p < 0.05).
Fig. 7

Proposed mechanism of action of pooled human immunoglobulin (PooledhlgG) on the reversal of the pathophysiology of smooth muscle inhibition by circulating M₃-R antibodies in SSc.

- **A**: Graph showing the effect of IFN (IVG) on OD at 450 nm with Peptide 400 µg/ml + SScIgG 5 µg/ml.
- **B**: Graph showing the effect of IFN (IVG) on OD at 450 nm with Lysate 400 µg/ml + SScIgG 5 µg/ml.
- **C**: Diagram illustrating the proposed mechanism involving PooledhlgG, Cholinergic Innervation, ACh, M₃-R, and abnormal GI motility.

In the diagram:
- **PooledhlgG** interacts with SScIgGs leading to M₃-R inactivation.
- **Cholinergic Innervation** releases ACh.
- **M₃-R inactivation** leads to abnormal GI motility.